Shoulder and Neck Mobilization in Patients With Subacromial Impingement Syndrome

August 10, 2026 updated by: Kutahya Health Sciences University

Effects of Shoulder and Neck Mobilization on Pain, Sensation and Functionality in Patients With Subacromial Impingement Syndrome

Patients who come to Tavşanlı State Hospital's Physical Therapy and Rehabilitation Department and have been diagnosed with subacromial impingement syndrome by a physician will be included. Patients will be selected by randomization method among the patients determined by the physician to receive conservative treatment, shoulder mobilization in addition to conservative treatment, and neck mobilization treatment program in addition to these. Conventional treatments such as hot packs, TENS, ultrasound, and exercise will be given to all patients by the hospital staff. Pain intensity will be evaluated with VAS. Additionally, painful arch and pain-free joint range of motion evaluation will be made using a goniometer. The DASH questionnaire will be used to evaluate shoulder functionality. Sensory evaluation will be made with pressure pain threshold and two-point discrimination tests. Measurements will be made before the intervention and repeated after 3 weeks of intervention.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
45

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Turkey (Türkiye)
      • Kütahya, Turkey (Türkiye), 43100
        • Kutahya Health Sciences University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Being over 18 years of age
  • Diagnosed with Subacromial Impingement
  • Not having received any treatment for shoulder problems in the last 6 months
  • The pain has been continuing for 3 months
  • Initial pain must be 4 or higher on the Visual Analog Scale (VAS)

Exclusion Criteria:

  • History of surgery in the shoulder, cervical and thoracic region
  • Having a shoulder problem such as a frozen shoulder or instability
  • Full-thickness rotator cuff tear
  • Having systemic musculoskeletal disease
  • Having systemic rheumatic disease
  • History of upper extremity fracture
  • Diagnosed with scoliosis
  • Have neurological problems

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Conventional treatment group
Hot packs, TENS, ultrasound, and exercise
Other: Conventional Treatment
Hot pack,TENS, ultrasound and exercises
Experimental: Conventional treatment + shoulder mobilization group
Hot packs, TENS, ultrasound, exercise, and shoulder mobilization
Other: Conventional Treatment
Hot pack,TENS, ultrasound and exercises
Other: shoulder mobilization
In the glenohumeral joint mobilization technique, distraction, anterior-posterior gliding, and inferior gliding movements will be applied.
Experimental: Conventional treatment + shoulder mobilization + neck mobilization group
Hot packs, TENS, ultrasound, exercise, and shoulder and neck mobilization
Other: Conventional Treatment
Hot pack,TENS, ultrasound and exercises
Other: shoulder mobilization
In the glenohumeral joint mobilization technique, distraction, anterior-posterior gliding, and inferior gliding movements will be applied.
Other: neck mobilization
Bridge, lateral flexion movement combined with traction, anterior-posterior gliding with traction, and lateral gliding techniques will be applied in neck mobilization.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Pain intensity
Time Frame: through study completion, an average of 1 year
Pain intensity will be evaluated with VAS. VAS is a valid and reliable self-report scale consisting of a 10 cm long horizontal line, with scores ranging from 0 (no pain) to 10 (worst pain imaginable). Participants are asked to report the maximum pain they experienced in the last 24 hours. A change of 1.5 points is considered a minimal clinically important difference (MCID) for the VAS.
through study completion, an average of 1 year

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
The Arm, Shoulder and Hand Problems (DASH) Questionnaire
Time Frame: through study completion, an average of 1 year
(DASH) questionnaire is a questionnaire that evaluates the functional level and disability of the entire upper extremity. At least 27 out of 30 questions must be answered for the inquiry to be evaluated. The query gives a value between 0-100. All questions are scored from 1 to 5. A higher score indicates greater disability.
through study completion, an average of 1 year
Painful arch assessment
Time Frame: through study completion, an average of 1 year
The patient is asked to abduct his arm as much as he can while standing or sitting. The test is positive if the patient feels pain between 60-120° of elevation. The sensitivity of the painful arc test performed in CNS patients was found to be 53% and the specificity was 80%.
through study completion, an average of 1 year
Painless range of motion assessment
Time Frame: through study completion, an average of 1 year
Painless ROM evaluation will be performed in CNS patients due to the presence of a painful arch. Pain-free ROM evaluation includes flexion and abduction movements occurring in the frontal and sagittal planes. These movements are evaluated using a universal goniometer. The patient is asked to actively create 2 movements in a standing or sitting position. While performing measurements with a goniometer, the part with pain-free ROM will be noted in degrees
through study completion, an average of 1 year
Pressure-pain Threshold Assessment
Time Frame: through study completion, an average of 1 year
Pressure pain threshold is the most commonly used method among quantitative sensory tests.Measurements will be taken from the upper trapezius, supraspinatus, and middle deltoideus muscles.
through study completion, an average of 1 year
Evaluation of Tactile Sensory Acuity
Time Frame: through study completion, an average of 1 year
Esthesiometer measurements will be taken from the surfaces corresponding to the C5, C6, and C7 dermatomes. To standardize the test areas, vertical lines will be drawn from the anterior, middle, and posterior edges of the acromion towards the elbow. The test will begin at 0 mm and the distance will first be gradually increased in 5 mm increments until the participant perceives two dots instead of one. When the participant reports detecting two dots, that distance will be recorded. Separate evaluations will be taken from 3 regions and the results will be recorded.
through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Kutahya Health Sciences University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Meltem Işıntaş, Kutahya Health Sciences University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 7, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 13, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 28, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 30, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 16, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 19, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 11, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 10, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2024/06-29

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings